Medication info
Esliptin Tablet 100 mg (Sitagliptin Hydrochloride Hydrate)

Esliptin Tablet 100 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
Light orange, round, biconvex film-coated tablet
Packaging
30 tablets - 10 tablets/PTP[x3]
Approval status
Active

MFDS item code 202004028 · Approved 2020.05.29 · Insurance code 660703770

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be taken alone alongside dietary and exercise therapy and is suitable for patients who have not previously used diabetes medications. If blood sugar control is difficult with monotherapy, it can be administered in combination with metformin. Additionally, it should also be taken with sulfonylurea, metformin, thiazolidinediones, or insulin when control is insufficient with these monotherapies. It can be additionally used in patients who struggle with blood sugar control even with combination therapy.

How to take

Adult dose

This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication can cause hypersensitivity reactions. If symptoms of allergy or severe skin conditions appear, discontinue use immediately and consult a physician. During use, symptoms of pancreatitis may occur; thus, if symptoms such as abdominal pain or vomiting appear, promptly inform a healthcare professional. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Patients with renal impairment should have their dose adjusted, and regular renal function tests are important. This medication can induce hypoglycemia, so when taken with insulin or sulfonylurea, careful monitoring of blood sugar levels is necessary. If severe joint pain or skin blistering symptoms occur, inform a doctor immediately, and discontinue the medication if necessary. Its use is not recommended during pregnancy; if breastfeeding, it is advisable to avoid taking this medication. Safety in children and adolescents has not been established, so it is preferable not to use it in individuals under 18 years of age. Elderly patients may have reduced renal function; therefore, dose adjustments and renal function tests are needed. In the event of overdose, immediately see a healthcare institution for appropriate treatment; some may be removed through hemodialysis. While taking this medication, symptoms of infection or gastrointestinal symptoms, headaches, dizziness, or other abnormal reactions may occur, so careful observation is required. There may be interactions with other medications, so inform the healthcare provider of all medications being taken.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory tract infection
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 31 more
  • nausea
  • constipation
  • vomiting
  • rash
  • urticaria
  • cutaneous vasculitis
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • acute kidney failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased ALT
  • increased AST
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture ingress. It is also advisable to store at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's efficacy for a longer period.

Appearance and packaging

Appearance

Light orange, round, biconvex film-coated tablet

Package unit

30 tablets - 10 tablets/PTP[x3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.